Blujepa (gepotidacin) – New drug approval
March 25, 2025 - GSK announced the FDA approval of Blujepa (gepotidacin), for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.
Top